Roche, 4D to develop AAV vectors

Roche (SIX:ROG; OTCQX:RHHBY) partnered with 4D Molecular Therapeutics LLC (San Francisco, Calif.) to use 4D's Directed Vector Evolution platform to develop next-generation adeno-associated viral (AAV) vectors.

4D co-founder and CEO David Kirn said the partners will target a series of undisclosed monogenic diseases. Kirn said 4D will generate the vectors and optimize them for specific tissue types and transgene payloads, while Roche will perform preclinical and clinical studies, and is responsible for global commercialization. ...